#Nicox #outlines #future #development #partnership #plans
- Result of the Mont Blanc Phase 3 study suggests potential ccommercial opportunity by NCX 470 in the uUnited States As a novel aalternative Treatment to lower intraocular pressure
- Plans to generate clinical Data strive for Demonstrate the potential retina advantages by NCX 470 in order to add significantly therapeutic value on the product profile in glaucoma
- intention to dishes the value of NCX 470 through the right commercially partnerships in the uUnited States and Japan
November 7th, 2022 – Release at 7:30am CET
Sophia Antipolis, France
Nicox S.A (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced future development and partnership plans for NCX 470, a novel bimatoprost nitric oxide (NO) donating eye drop, currently in phase 3 of development to lower ophthalmology intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
“Our market research shows a Unmet need in glaucoma treatment with focus on intraocular depression…
Read on GNW: Nicox outlines future development and partnership plans for
